The search for potential hypotensive peptides in the amino acid sequence of human renalase and their identification in proteolytic fragments of this protein

• Published in: Biomeditsinskaia khimiia Vol. 69; no. 6; p. 403
• Main Authors: Fedchenko, V I, Veselovsky, A V, Kopylov, A T, Medvedev, A E
• Format: Journal Article
• Language: English
• Published: Russia (Federation) 01-12-2023
• Subjects: Amino Acid Sequence; Antihypertensive Agents; Humans; Monoamine Oxidase; Peptide Fragments; Peptides; biological activity; peptide inhibitors of angiotensin-converting enzyme; renalase; renalase peptides; proteolytic processing
• ISSN: 2310-6972
• DOI: 10.18097/PBMC20236906403

Renalase (RNLS) is a secretory protein discovered in 2005. It plays an important role in the regulation of blood pressure. Studies by two independent laboratories have shown that administration of purified recombinant RNLS reduced blood pressure in experimental animals. However, the mechanisms of the antihypertensive effect of RNLS still remain unclear, especially in the context of the shift in the catalytic paradigm of this protein. In addition, there is growing evidence that endogenous plasma/serum RNLS, detected by enzyme immunoassay, is not an intact protein secreted into the extracellular space, and exogenous recombinant RNLS is effectively cleaved during short-term incubation with human plasma samples. This suggests that the antihypertensive effect of RNLS may be due to peptides formed during proteolytic processing. Based on the results of a bioinformatics analysis of potential RNLS cleavage sites (Fedchenko et al., Medical Hypotheses, 2022; DOI: 10.1016/j.mehy.2022.110895), a number of short peptides have been identified in the RNLS sequence that show similarity to fragments of known peptide inhibitors of angiotensin-converting enzyme. Some of them were found as a part of larger RNLS peptides, formed during RNLS cleavage by chymotrypsin and, and to a lesser extent, by trypsin.